Search results
Results From The WOW.Com Content Network
Physical activity before cancer diagnosis is associated with a decreased risk of cancer progression and death, a new study, which focused mostly on breast and prostate cancer patients, found.
If all cancer patients survived and cancer occurred randomly, the normal lifetime odds of developing a second primary cancer (not the first cancer spreading to a new site) would be one in nine. [29] However, cancer survivors have an increased risk of developing a second primary cancer, and the odds in 2003 were about one in 4.5. [29]
A patient with working heart and lungs who is determined to be brain dead can be pronounced legally dead without clinical death occurring. However, some courts have been reluctant to impose such a determination over the religious objections of family members, such as in the Jesse Koochin case. [ 30 ]
In epidemiology, case fatality rate (CFR) – or sometimes more accurately case-fatality risk – is the proportion of people who have been diagnosed with a certain disease and end up dying of it. Unlike a disease's mortality rate , the CFR does not take into account the time period between disease onset and death.
“We found that working adults living alone had a 1.32 times higher risk of cancer death than adults living with others,” said Dr. Farhad Islami, an author of the study and senior scientific ...
Meanwhile, the cancer death rate is declining, the new findings show, falling by a third from 1991 to 2021. ... Seven modifiable risk factors are responsible for 40% of cancers, according to the ...
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
A young patient with an “aggressive-looking” prostate cancer, whose father had the condition and who carries a BRCA2 mutation, is an entirely different patient from “an 80-year-old man who ...